Australia's most trusted
source of pharma news
Tuesday, 24 February 2026
Posted 24 February 2026 AM
Arrotex is pushing into the innovative medicines space, announcing a licensing deal with Taiwan-based Formosa for an innovative post-surgery topical eyedrop in Australia and New Zealand.
The Aussie giant has won exclusive rights to commercialise the treatment with upfront, regulatory milestones, sales milestones, and royalty considerations throughout the terms of the agreement.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.